Roxro Pharma gets $21.65M commitment for pain management
Roxro Pharma, a Menlo Park developer of drugs for acute pain management, has won $21.65 million more in commitments to extend its second round of funding, VentureWire reports (sub required).
The financing came from the company’s existing Series B investors: Prospect Ventures, Sutter Hill Ventures, Thomas Weisel Healthcare Venture Partners, Mediphase Venture Partners, Voyager Funds and Fimei SpA, said Roberto Rosenkranz, chairman and chief executive of Roxro. The company raised an original $21.65 million in Series B financing in September 2005 from the same investors.
Next Story: Private equity fund-raising hits $177 billion, sets record
Previous Story: Oracle buys software cos, Stellant for $440M, and SPL
VB Writers
Ben PopperEast Coast Editor
Dean TakahashiLead Writer, GamesBeat
Devindra HardawarNational Editor, MobileBeat Lead
Dylan TweneyExecutive Editor
ShoeEditor-in-Chief, GamesBeat
Heather KellySenior Editor
Jennifer Van GroveWriter
Jolie O'DellWriter
Matt MarshallFounder & Editor-in-Chief
Meghan KellyWriter
Sarah MitroffEditorial Assistant
Sean LudwigWriter
Sebastian HaleyReviews Editor, GamesBeat
Tom CheredarWriter
Ciara ByrneContributor
Julia PlevinContributor
Lindsey ComptonContributor
